Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?
作者信息
Poschenrieder Andreas, Taleska Jasminka, Schaetz Leonhard
机构信息
Advanced Accelerator Applications, Novartis, Geneva, Switzerland; and.
Novartis Pharma AG, Basel, Switzerland
出版信息
J Nucl Med. 2024 Sep 3;65(9):1340-1342. doi: 10.2967/jnumed.124.267951.
Abstract
摘要
相似文献
1
Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?镥-PSMA（R）在癌症治疗中的变革：它真的在发生吗？
J Nucl Med. 2024 Sep 3;65(9):1340-1342. doi: 10.2967/jnumed.124.267951.
2
Preparation of Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.医院放射性药物制备：使用内部开发的单瓶冻干 PSMA-617 试剂盒方便地配制临床剂量。
Biomed Res Int. 2021 Nov 20;2021:1555712. doi: 10.1155/2021/1555712. eCollection 2021.
3
Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.使用（177）Lu标记的PSMA抑制剂进行前列腺癌靶向治疗中中等比活度（177）Lu的前景。
J Labelled Comp Radiopharm. 2016 Jul;59(9):364-71. doi: 10.1002/jlcr.3414. Epub 2016 Jun 6.
4
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
5
Value of post-therapy Lu-PSMA images for accurate interpretation of therapy response with Ga-PSMA PET/CT.治疗后镥-PSMA图像对于准确解读镓-PSMA PET/CT治疗反应的价值。
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Mar-Apr;37(2):114-117. doi: 10.1016/j.remn.2017.05.004. Epub 2017 Jul 24.
6
Evaluation of Lu and Sc Picaga-Linked, Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry.Lu 和 Sc 双载前列腺特异性膜抗原靶向构建物的放射治疗疗效和剂量学评价。
Mol Pharm. 2021 Dec 6;18(12):4511-4519. doi: 10.1021/acs.molpharmaceut.1c00711. Epub 2021 Oct 29.
7
Survey of Clinical Protocols for the Use of Lu-PSMA-617 in the United States.美国 Lu-PSMA-617 使用临床方案调查。
J Nucl Med Technol. 2024 Sep 5;52(3):208-211. doi: 10.2967/jnmt.123.266769.
8
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.[吕]Lu-PSMA-617 对比卡巴他赛用于转移性去势抵抗性前列腺癌（TheraP）患者：一项随机、开放标签、2 期试验。
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
9
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.探索外照射放疗与[镥]镥-PSMA-617靶向放射性配体疗法联合用于前列腺癌的作用——从实验室到临床应用
Theranostics. 2024 Apr 8;14(6):2560-2572. doi: 10.7150/thno.93249. eCollection 2024.
10
Systematic Review of the First 40 Cases of Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer.Lu-PSMA 疗法治疗非前列腺癌的前 40 例病例系统评价。
Anticancer Res. 2024 Jun;44(6):2297-2305. doi: 10.21873/anticanres.17037.
引用本文的文献
1
Multifactorial analysis of radiochemical purity in high-activity Lu-labeled theranostics: impact of precursor source, Lu form, and production parameters.高活性镥标记诊疗剂放射化学纯度的多因素分析：前体来源、镥形态及生产参数的影响
EJNMMI Radiopharm Chem. 2025 Jul 22;10(1):47. doi: 10.1186/s41181-025-00372-5.
2
Development of [Tc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer.[锝]锝-高锝酸盐-ABX474的研发：用于前列腺癌单光子发射计算机断层显像的前列腺特异性膜抗原结合锝-99m放射性配体的设计、合成及生物学评价
J Med Chem. 2025 Apr 10;68(7):7213-7231. doi: 10.1021/acs.jmedchem.4c02767. Epub 2025 Mar 26.
3
Feasibility of Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer.镥-PSMA给药作为前列腺癌门诊治疗程序的可行性。
J Nucl Med. 2024 Dec 3;65(12):1848-1849. doi: 10.2967/jnumed.124.268062.
本文引用的文献
1
Radiotheranostics Global Market and Future Developments.放射性药物全球市场与未来发展。
Semin Nucl Med. 2024 Jul;54(4):622-633. doi: 10.1053/j.semnuclmed.2024.02.003. Epub 2024 Mar 13.
2
Overall survival with [Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.LuLu-PSMA-617 对比卡巴他赛用于转移性去势抵抗性前列腺癌（TheraP）的总生存期：一项随机、开放标签、2 期临床试验的次要结局。
Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30.
3
Health-related quality of life and pain outcomes with [Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.LuLu-PSMA-617 联合标准护理与标准护理治疗转移性去势抵抗性前列腺癌患者的健康相关生活质量和疼痛结局（VISION）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4.
4
Radioligand therapies in cancer: mapping the educational landscape in Europe.癌症的放射性配体疗法：绘制欧洲的教育图谱。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2692-2698. doi: 10.1007/s00259-023-06217-0. Epub 2023 Apr 14.
5
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer.在美国，将放射性配体疗法纳入前列腺癌患者的临床实践中。
Cancer Treat Rev. 2023 Apr;115:102524. doi: 10.1016/j.ctrv.2023.102524. Epub 2023 Feb 11.
6
How Many Theranostics Centers Will We Need in the United States?在美国我们将需要多少个治疗诊断中心？
J Nucl Med. 2022 Jun;63(6):805-806. doi: 10.2967/jnumed.122.264144.
7
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
8
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.PSMA 放射性配体疗法治疗除前列腺癌以外的实体瘤：背景、机遇、挑战和初步临床报告。
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4350-4368. doi: 10.1007/s00259-021-05433-w. Epub 2021 Jun 12.
Zotero 插件